Core Biogenesis announced the launch of Peaureva, a biotechnology-derived scalp active designed to address hair thinning and scalp aging. The company will debut this new ingredient at in-cosmetics Global 2026 in Paris, France.
According to the company’s press release, Peaureva was developed to target the biological mechanisms that influence follicle activity and scalp health. Core Biogenesis’ researchers identified five biological drivers that contribute to hair density decline:
- Hair cycle dysregulation
- Reduced dermal papilla signalling
- Declining microvascular support around follicles
- Progressive thinning of hair fibers
- Deterioration of the scalp barrier environment.
Peaureva is centered by fibroblast growth factor-2 (FGF-2), a signalling growth factor protein involved in tissue regeneration and hair follicle physiology. This protein supports the biological processes essential to hair growth. Researchers at Core Biogenesis developed an oleosome-based delivery system to enable the use of FGF-2 in cosmetic formulation.
“Hair thinning is often treated as a cosmetic problem, but the underlying changes occur at the level of follicle biology and the scalp microenvironment,” said chief commercial officer Tony Abboud. “With Peaureva, we are applying biomimetic growth factors and advanced delivery technology to support several biological drivers of scalp aging simultaneously. These early clinical results illustrate how biotechnology may help redefine performance expectations for topical haircare ingredients.”
Peaureva was evaluated in a randomized, single-blind, placebo-controlled clinical study of 40 volunteers. According to the clinical results, 33.6% of participants saw an increase in hair density and 17.5% saw an increase in scalp hydration after 28 days.
